Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global epigenomics market is expected to grow at a CAGR of 13.1% during the period 2022-2027. Several companies offer microarrays containing gene promoters, CpG islands, or whole genomes for scientists to look for methylation at sites using MeDIP. Modern techniques enable scientists to study epigenetic changes across entire genomes and determine how and where such changes occur. Scientists seek a better understanding of the occurrence of epigenetic changes and their consequences. Further, by identifying patterns of methylation tags across the whole genome and of histone modifications in various kinds of cells and tissues, it would be possible for scientists to recognize "signatures" associated with certain biological processes or disease states. North America, Europe and Asia are expected to be key markets.
Epigenomics refers to the study of the epigenome – a host of chemical compounds directing the functioning genome as a whole. These compounds attach to the DNA to activate or deactivate particular genes in the genome, changing its behaviour. Thus, the epigenome may influence regulation of protein production in some cells of the body. Researchers monitor locations and understand the functions of all the chemical tags marking the genome. When epigenomic compounds bind to DNA and alter its function, it is said that these compounds have "marked" the genome. While these marks do not change the DNA sequence, they alter the way cells use the DNA's instructions. The marks are occasionally passed on from cell to cell as cells divide. These also can be passed down from generation to generation.
There are trillion of cells in a human being; these cells have specific functions in the muscles, bones and brain, and each cell contains fundamentally the same genome in its nucleus. The way and when the different gene sets are turned on or off in different types of cells determine differences among cells. For example, specific cells in the eye turn on genes producing proteins that may detect light; particular cells in red blood cells produce proteins carrying oxygen from the air to the rest of the body. The epigenome regulates several of these changes to the genome. The epigenome is the group of chemical modifications to the DNA and DNA-associated proteins in the cell, altering gene behaviour, and are heritable (through meiosis and mitosis). The modifications take place as a natural process of development and tissue differentiation, and may be changed in response to environmental exposures or disease.
The first type of mark, known as DNA methylation, directly influences the DNA in a genome. In the process, proteins bind chemical tags called methyl groups to the bases of the DNA molecule in particular places. The methyl groups turn genes on or off by influencing interactions between the DNA and other proteins. Thus, cells can remember which genes are on or off. The second type of mark, called histone modification, influences DNA indirectly. DNA in cells is wrapped around histone proteins, forming spool-like structures enabling DNA's very long molecules to be coiled up neatly into chromosomes within the cell nucleus. Proteins can bind several chemical tags to histones. Other proteins in cells can identify these tags and decide whether that region of DNA should be used or ignored in the cell.
Lifestyle and environmental factors (which include smoking, diet and infectious disease) could expose an individual to pressures that induce chemical responses. These responses, in turn, could cause changes in the epigenome; some changes could be damaging. Cancers could be caused by changes in the genome, the epigenome, or both. Changes in the epigenome could switch on or off genes engaged in cell growth or the immune response, causing uncontrolled growth (a sign of cancer), or leading to a failure of the immune system to destroy tumours.
In cases of glioblastoma (a kind of brain tumour), the drug temozolomide has been used with some success; the drug kills cancer cells by attaching methyl groups to DNA. In some cases, methylation shows another positive – it blocks a gene that counteracts temozolomide. Patients with glioblastoma who have tumours with such methylated genes are more likely to respond to temozolomide as compared to those with unmethylated genes. Changes in the epigenome could also trigger growth-promoting genes in colon cancer, stomach cancer, and the most common type of kidney cancer. In some other types of cancer, changes in the epigenome stifle genes that generally help regulate cell growth.
Several research groups are engaged in an attempt to characterize the epigenome, and recognize, catalogue, and understand genome-wide DNA methylation patterns of all human genes in all key tissues. Such associations are multinational and multidisciplinary, and characterize the highest quality of research. Epigenomics, as a domain, has the potential to examine and reveal nongenetic components of complex diseases. It is hoped that with full genome sequence and epigenomic maps of the DNA methylation and modified histone landscapes, it would be possible to identify the exact genes that activated, and in which tissues. Such information would provide new ways to diagnose and treat complex diseases, and is expected to drive the global epigenomics market.
By technology, the global epigenomics market is segmented into:
By product type, the market is divided into:
By application, the market is classified into:
By region, the market is segmented into:
The report presents a detailed analysis of the following key players in the global epigenomics market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Technology||
|Breakup by Product Type||
|Breakup by Application||
|Breakup by Region||
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
7 Industry Opportunities and Challenges
8 Global Epigenomics Market Analysis
8.1 Key Industry Highlights
8.2 Global Epigenomics Historical Market (2017-2021)
8.3 Global Epigenomics Market Forecast (2022-2027)
8.4 Global Epigenomics Market by Technology
8.4.1 Histone Methylation
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2017-2021)
126.96.36.199 Forecast Trend (2022-2027)
8.4.2 Large Non-Coding RNA
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2017-2021)
220.127.116.11 Forecast Trend (2022-2027)
8.4.3 MicroRNA Modification
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2017-2021)
126.96.36.199 Forecast Trend (2022-2027)
8.4.4 DNA Methylation
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2017-2021)
220.127.116.11 Forecast Trend (2022-2027)
8.4.5 Chromatin Structures
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2017-2021)
126.96.36.199 Forecast Trend (2022-2027)
8.5 Global Epigenomics Market by Product Type
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2017-2021)
220.127.116.11 Forecast Trend (2022-2027)
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2017-2021)
126.96.36.199 Forecast Trend (2022-2027)
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2017-2021)
220.127.116.11 Forecast Trend (2022-2027)
8.6 Global Epigenomics Market by Application
18.104.22.168 Market Share
22.214.171.124 Historical Trend (2017-2021)
126.96.36.199 Forecast Trend (2022-2027)
188.8.131.52 Market Share
184.108.40.206 Historical Trend (2017-2021)
220.127.116.11 Forecast Trend (2022-2027)
8.7 Global Epigenomics Market by Region
8.7.1 Market Share
18.104.22.168 North America
22.214.171.124 Asia Pacific
126.96.36.199 Latin America
188.8.131.52 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
184.108.40.206 United States of America
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
220.127.116.11 United Kingdom
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
18.104.22.168 Saudi Arabia
22.214.171.124 United Arab Emirates
126.96.36.199 South Africa
10 Market Dynamics
10.1 SWOT Analysis
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Epigenomics AG
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
220.127.116.11 Demographic Reach and Achievements
11.2.2 Illumina, Inc.
18.104.22.168 Company Overview
22.214.171.124 Product Portfolio
126.96.36.199 Demographic Reach and Achievements
11.2.3 Merck KGaA
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
220.127.116.11 Demographic Reach and Achievements
11.2.4 Zymo Research Corporation
18.104.22.168 Company Overview
22.214.171.124 Product Portfolio
126.96.36.199 Demographic Reach and Achievements
11.2.5 Agilent Technologies, Inc.
188.8.131.52 Company Overview
184.108.40.206 Product Portfolio
220.127.116.11 Demographic Reach and Achievements
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Epigenomics Market: Key Industry Highlights, 2017 and 2021
2. Global Epigenomics Historical Market: Breakup by Technology (USD Million), 2017-2021
3. Global Epigenomics Market Forecast: Breakup by Technology (USD Million), 2022-2027
4. Global Epigenomics Historical Market: Breakup by Product Type (USD Million), 2017-2021
5. Global Epigenomics Market Forecast: Breakup by Product Type (USD Million), 2022-2027
6. Global Epigenomics Historical Market: Breakup by Application (USD Million), 2017-2021
7. Global Epigenomics Market Forecast: Breakup by Application (USD Million), 2022-2027
8. Global Epigenomics Historical Market: Breakup by Region (USD Million), 2017-2021
9. Global Epigenomics Market Forecast: Breakup by Region (USD Million), 2022-2027
10. North America Epigenomics Historical Market: Breakup by Country (USD Million), 2017-2021
11. North America Epigenomics Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Europe Epigenomics Historical Market: Breakup by Country (USD Million), 2017-2021
13. Europe Epigenomics Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Asia Pacific Epigenomics Historical Market: Breakup by Country (USD Million), 2017-2021
15. Asia Pacific Epigenomics Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Latin America Epigenomics Historical Market: Breakup by Country (USD Million), 2017-2021
17. Latin America Epigenomics Market Forecast: Breakup by Country (USD Million), 2022-2027
18. Middle East and Africa Epigenomics Historical Market: Breakup by Country (USD Million), 2017-2021
19. Middle East and Africa Epigenomics Market Forecast: Breakup by Country (USD Million), 2022-2027
20. Global Epigenomics Market Structure
The global epigenomics market is projected to grow at a CAGR of 13.1% between 2022 and 2027.
The major drivers of the market include the increasing shift towards personalised medicines, rising prevalence of diseases such as cancer, decreasing sequencing costs, increasing research activity, and growing applications of epigenetics in non-oncology diseases.
The growing need to study complex diseases and increased funding for research in the field of epigenomics are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The various technologies involved in the market are histone methylation, large non-coding RNA, microRNA modification, DNA methylation, and chromatin structures, among others.
Based on product type, the market is segmented into kits, reagents, and enzymes, among others.
The significant applications of the market are diagnostics and pharmaceuticals.
The major players in the industry include Epigenomics AG, Illumina, Inc., Merck KGaA, Zymo Research Corporation, and Agilent Technologies, Inc., among others.
The global epigenomics market was driven by the growing need to study complex diseases in the historical period. Aided by the rising prevalence of diseases such as cancer and increased funding for research in the field of epigenomics, the market is expected to grow at a CAGR of 13.1% in the forecast period of 2022-2027.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The various technologies involved in the market are histone methylation, large non-coding RNA, microRNA modification, DNA methylation, and chromatin structures, among others. Based on product type, the market is segmented into kits, reagents, and enzymes, among others. The significant applications of the market can be divided into diagnostics and pharmaceuticals. The major regional markets for epigenomics are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The major players in the market are Epigenomics AG, Illumina, Inc., Merck KGaA, Zymo Research Corporation, and Agilent Technologies, Inc., among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.